Crelux and 4SC granted AiCuris rights to commercialize small molecule compounds discovered by Crelus and 4SC using their idea-to-candidate (i2c) platform targeting infectious diseases

4SC AG

Germany / Small-Cap Biopharma (<$1 billion)

$123.7m on 11/08/2013 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Crelux GmbH

Germany / Tools, Services, and Manufacturing

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

AiCuris GmbH & Co. KG

Germany / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced